ALDX
$1.81-0.02 (-1.09%)
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
Recent News
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.
FDA issues CRL to Aldeyra’s reproxalap drug application
During the review process, the FDA provided label drafts in December 2025 and March 2026.
Aldeyra Therapeutics Shares Fall Pre-Bell After US FDA Response Cites Lack of Efficacy Data for Dry Eye Drug
Aldeyra Therapeutics (ALDX) shares were down more than 73% in recent Tuesday premarket activity afte
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.